Non-steroidal anti-inflammatory drugs (NSAIDs) are the second most common group of drugs leading to the development of drug-induced liver injury (DILI). Objective: to determine the clinical features of DILI in patients with gout when using NSAIDs.Material and methods. The study is monocentric, observational, retrospective. Performed in the period from 2012–01–01 to 2020–12–31 in the heumatology Department of the 11th City Clinical Hospital. The study included 527 patients with gouty arthritis (GA). The type of DILI was determined in accordance with the recommendations of EASL, 2019. An updated scale RUCAM (Roussel Uclaf Causality Assessment Method) was used to assess causal relationships.Results. DILI was detected in 91 patients (14.3 %), in 80 – hepatocellular, in 11 – mixed type of DILI. The 1st category of DILI severity was stated in 88, the 2nd category – in 3 patients. We observed DILI more often in younger patients without severe comorbidity, but with an alcoholic surplus preceding a GA attack and, after, during attack an excess of the average therapeutic doses of NSAIDs was registered. Conclusions. Thus, we did not observe a severe course of DILI in patients taking NSAIDs for the relief of GA. However, NSAID hepatotoxicity in this category of patients is a social and medical problem.
- 1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines Drug-induced liver injury // J of Hepatology. – 2019. – Vol. 30. – P. 1–40.
- 2. Schmeltzer, P. A., Kosinski A. S., Kleiner D. E. et al. Liver injury from nonsteroidal anti-inflammatory drugs in the United States // Liver International. – 2016. – Vol. 36(4). – P. 603–609.
- 3. Fontana, R. J., Seeff L. B., Andrade R. J. et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop // Hepatology. – 2010. – № 52(2). – Р. 730–42.
- 4. Wei, G. A., Broom B. U. Acute liver failure in Sweden: etiology and outcome // Journal of Internal Medicine. – 2007. – Vol. 262. – Р. 393–401.
- 5. Pichette, P., Doherty M., Pascual E. et al. 2016 Updated EULAR evidence-based recommendations for the management of gout // Ann Rheum Dis. – 2017. – № 76(1). – Р. 29–42.
- 6. Bjornsson, E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease // Hepatology. – 2005. – № 42. – Р. 481–9 (ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury).
- 7. Ивашкин, В. Т., Барановский А. Ю., Райхельсон К. Л. и др. Лекарственные поражения печени (клинические рекомендации для врачей) // Российский журнал гастроэнтерологии, Гепатологии, колопроктологии. – 2019. – № 29(1). – С. 85–115.
- 8. Wallace, S., Robinson H., Masi A. et al. Preliminary criteria for the classification of the acute arthritis of primary gout // Arthritis Rheum. – 1977. – № 20. – Р. 895–900.